Supplemental Material

Appendix

Study contributors

Study Administration Office

Toho University Ohashi Medical Center Raisuke Iijima

Steering Committee

Kurashiki Central Hospital Kazushige Kadota

Saiseikai Kumamoto Hospital Koichi Nakao

Fukuoka Sanno Hospital Hiroyoshi Yokoi

Saiseikai Nakatsu Hospital Junya Shite

Tenri Hospital Yoshihisa Nakagawa

Teikyo University School of Medicine Ken Kozuma

Mitsui Memorial Hospital Kengo Tanabe

Advisory Board

Shonan Kamakura General Hospital Shigeru Saito

Nihon University School of Medicine Atsushi Hirayama

Kurume University Hospital Takafumi Ueno

Wakayama Medical University Takashi Akasaka

Kawasaki Medical School Shiro Uemura

Kobe University Graduate School of Medicine Toshiro Shinke

Clinical Events Committee

Ischemic Events

Tokyo Medical University Hachioji Medical

Center Nobuhiro Tanaka

Nihon University School of Medicine Tadateru Takayama

Yokohama City University Medical Center Kiyoshi Hibi

Toranomon Hospital Yuji Matsumaru

Bleeding Events

Juntendo University Graduate School of

Medicine Katsumi Miyauchi

Tokyo Medical University Hospital Takashi Kawai

Kyushu University Takanari Kitazono

Pharmacodynamics evaluation adviser

Mie University Hospital Masakatsu Nishikawa

Tohoku University Hisanori Horiuchi

Statisticians

Toho University Yoshitaka Murakami

Data Coordination

Statistical Analysis Statcom CO., Ltd.

Data Management CMIC CO., Ltd.

Electronic Data Capture Meditrix CO., Ltd

Study Institutions and Investigators

Institution	Investigator
Toho University Ohashi Medical Center	Masato Nakamura
	Norihiro Kogame
	Raisuke Iijima
	Katsushi Amemiya
Wakayama Medical University	Takashi Akasaka
	Takashi Kubo
	Yasushi Ino
Kurume University Hospital	Takafumi Ueno
	Masahiro Sasaki
Kurashiki Central Hospital	Kazushige Kadota
	Shunsuke Kubo
Teikyo University School of Medicine	Hiroyuki Kyono
Saiseikai Nakatsu Hospital	Junya Shite
	Yoichi Kijima
Kobe University Hospital	Toshiro Shinke
	Natsuko Tahara
	Hiromasa Otake
	Shinsuke Nakano
Mitsui Memorial Hospital	Kengo Tanabe
Saiseikai Kumamoto Hospital	Tomohiro
1	Sakamoto
	Shinzo Miyamoto
	Koichi Nakao
	Hiroto Suzuyama

Tenri Hospital Yoshihisa
Nakagawa

Soichiro Enomoto

Shunsuke Nishimura

Toshihiro Tamura

Juntendo University Hospital Hiroshi Iwata

Fukuoka Sanno Hospital Hiroyoshi Yokoi

Koji Ozaki

Yuji Murakami

Yokohama City University Medical Center Kiyoshi Hibi

Nobuhiko Maejima

Nihon University Itabashi Hospital Atsushi Hirayama

Daisuke Fukamachi

Tadateru Takayama

Yasuo Okumura

Fukui Cardio Vascular Center Sumio Mizuno

Yosuke Takazawa

Kazuo Osato

Nagoya University Hospital Toyoaki Murohara

Hideki Ishii

Susumu Suzuki

Akihito Tanaka

Naoki Iwakawa

Hiroshi Tashiro

Tokyo Kamata Hospital Naoto Inoue

Tokyo Women's Medical University Hospital Nobuhisa Hagiwara

Hisao Otsuki

Junichi Yamaguchi

University of Occupational and Environmental Health,

Japan

Shinjo Sonoda

Hironori Takami

Akiyoshi Shimizu

Toshiya Miura

Ageo Central General Hospital Takaaki Isshiki

Naoki Masuda

Edogawa Hospital Hiroshi Ohira

Tokyo Metropolitan Tama Medical Center Hiroyuki Tanaka

Yuya Mitsuhashi

St. Luke's International Hospital

Nobuyuki

Komiyama

Sakakibara Heart Institute Tetsuya Tobaru

Tomofumi Tanaka

Itaru Takamisawa

Showa University Northern Yokohama Hospital Seitaro Ebara

Juntendo University Shizuoka Hospital Satoru Suwa

Nagoya Kyoritsu Hospital Daisuke Kamoi

Takashi Sakakibara

Norio Umemoto

Matsusaka Central Hospital Takashi Tanigawa

Sakurabashi Watanabe Hospital Kenshi Fujii

Kobe City Medical Center General Hospital Yutaka Furukawa

Natsuhiko Ehara

The Jikei University Hospital Takayuki Ogawa

Kazuo Ogawa

Yasunori Inoue

Odawara Cardiovascular Hospital Itaru Yokouchi

Satoru Toi

Kenji Yamazaki

Tokushima University Hospital Tetsuzo Wakatsuki

Koji Yamaguchi

Chikamori Hospital Kazuya Kawai

Satoshi Yamamoto

Ota Memorial Hospital Hitoshi Anzai

Yoshinori Nagashima

Tokyo Medical University Hospital Jun Yamashita

Tokyo Women's Medical University Yachiyo Medical

Center

Shoji Haruta

Honda Atsushi

Yasutaka Imamura

Toru Isoda

Katsuya Suzuki

Ogikubo Hospital Yasuhiro Ishii

Masato Otsuka

Saiseikai Kawaguchi General Hospital Atsushi Takagi

Yutaka Terajima

Rinku General Medical Center Yoshihiro Takeda

Kawasaki Medical School Hospital Shiro Uemura

Teruyoshi Kume

Tomohiro

Kawasaki

Shin-Koga Hospital

Tokyo Medical University Hachioji Medical Center Nobuhiro Tanaka

Sakurakai Takahashi Hospital Akihiko Takahashi

Osaka National Hospital Yasunori Ueda

Kensuke Yokoi

Osaka University Hospital Yasushi Sakata

Masaki Awata

Takashi Kitao

Isamu Mizote

Tatsuya Shiraki

Miyazaki Medical Association Hospital Yoshisato Shibata

Nehiro Kuriyama

Hyogo Prefectural Awaji Medical Center Takatoshi Hayashi

Takumi Inoue

Kansai Rosai Hospital Takayuki Ishihara

Tokyo Rosai Hospital Takashi Yoshitama

Yuuji Yamashita

Fujisawa City Hospital Kengo Tsukahara

Kei Nishikawa

Takayuki

Mitsuhashi

Yokohama City University Hospital Teruyasu Sugano

Masayoshi

Kiyokuni

Naohiro Komura

Naoki Nakayama

Kiwamu Iwata

Funabashi Municipal Medical Center Shigeru Fukuzawa

Dokkyo Medical University Hospital Masashi Sakuma

Hyogo Brain and Heart Center Yoshinori Yasaka

Takahiro Sawada

Yokohama Sakae Kyosai Hospital Ichiro Michishita

Taku Iwaki

Tokushima Red Cross Hospital Koichi Kishi

Ogaki Municipal Hospital Yasuhiro Morita

Japanese Red Cross Okayama Hospital Tetsuya Sato

Soichiro Fuke

Asahi General Hospital Junji Kanda

Tokushima Prefectural Central Hospital Hiroyuki Fujinaga

Hirofumi

Yamamoto

Saiseikai Utsunomiya Hospital Takashi Yagi

Koji Ueno

Showa University Hospital Hiroaki Tsujita

Hiroshima Prefectural Hospital Hironori Ueda

Fujita Health University Hospital Yukio Ozaki

Masanori Okumura

Shiga General Hospital Masaharu Okada

Osaka Police Hospital Yoshiharu Higuchi

Shimpei Nakatani

Study institutes

	Number of
Institute	patients
Kurashiki Central Hospital	349
Toho University Ohashi Medical Center	282
Sakurakai Takahashi Hospital	265
Asahi General Hospital	253
Ota Memorial Hospital	218
Miyazaki Medical Association Hospital	202
Ogikubo Hospital	202
Hyogo Brain and Heart Center	157
Kawasaki Medical School	153
Sakakibara Heart Institute	150
Rinku General Medical Center	146
Tokyo Women's Medical University	146
Kansai Rosai Hospital Cardiovascular Center	143
Tokyo Medical University Hachioji Medical Center	143
Juntendo University Shizuoka Hospital	139
Chikamori Hospital	130
Tokyo Women's Medical University Yachiyo Medical Center	124
Ageo Central General Hospital	115
Tokyo Kamata Hospital	114
Fujisawa City Hospital	108
Tokushima Prefectural Central Hospital	102
Hiroshima Prefectural Hospital	100
Saiseikai Utsunomiya Hospital	100

100
100
100
100
100
97
97
92
89
88
86
86
82
75
74
74
73
71
71
64
63
56
54
53
52
51

Saiseikai Kawaguchi General Hospital	50
Tokyo Metropolitan Tama Medical Center	45
Fujita Health University Hospital	44
Nagoya University Graduate School of Medicine	43
Hyogo Prefectural Awaji Medical Center	41
University of Occupational and Environmental Health	39
Ogaki Municipal Hospital	36
The Jikei University School of Medicine	35
Saiseikai Kumamoto Hospital	30
St. Luke's International Hospital	29
Kobe University Graduate School of Medicine	28
Odawara Cardiovascular Hospital	28
Dokkyo Medical University	25
Nagoya Kyoritsu Hospital	15
Teikyo University School of Medicine	14
Yokohama City University Hospital	14
Osaka University Graduate School of Medicine	13
Juntendo University Graduate School of Medicine	4

Data S1. Definitions used in this study

Definition of the efficacy events

(1) Death

All deaths from any cause.

All-cause death: All deaths are applicable regardless of the cause.

Cardiovascular death: Deaths resulting from damage to the cardiac vessels.

(2) Non-fatal myocardial infarction

Non-fatal myocardial infarction is defined as myocardial infarction that is nonfatal based on diagnosis by markers for cardiomyopathy (cardiac enzymes) or electrocardiogram* etc. in the presence of symptoms suggestive of a new onset of acute myocardial infarction or reinfarction after index percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG).

*An ST change of $\geq \pm 1$ mm (0.1 mV) (new onset or recurrence) or a new Q wave abnormality is observed.

(3) Non-fatal stroke

A patient has cerebral stroke when neurologic symptoms or signs newly develop and when the culprit lesion is detected by computed tomography (CT) or magnetic resonance imaging (MRI) scans. Cerebral stroke is divided into two major subtypes:

ischemic stroke (cerebral infarction) and nonischemic stroke (e.g., cerebral hemorrhage, subarachnoid hemorrhage).

Ischemic stroke (cerebral infarction): A new onset of neurological signs or symptoms with a new infarct lesion related to the neurological signs or symptoms, which is confirmed by CT or MRI scans, regardless of whether the neurological signs or symptoms last at least 24 hours or not.

Nonischemic stroke: Cerebral hemorrhage, subarachnoid hemorrhage, etc.

(4) Revascularization

Revascularization is defined as unscheduled (emergent) PCI, CABG, or intracoronary thrombolysis introduced after index PCI or CABG.

· Target Lesion Revascularization

Repeat PCI or CABG for the target lesion (proximal and distal 5-mm-long segments from the edge of the implanted stent) due to restenosis of the target lesion or other complications.

· Target Vessel Revascularization

Repeat PCI or CABG for the target vessel due to restenosis of the target vessel or other complications.

(5) Transient ischemic attack (TIA)

TIA is defined as transient episodes of neurologic dysfunction caused by focal cerebral, spinal cord, and retinal ischemia. CT and MRI scans reveal no evidence of acute infarction.

(6) Stent thrombosis

Stent thrombosis is defined as definite, probable, or possible stent thrombosis by the

Academic Research Consortium classification.

(7) Peripheral arterial occlusive disease

Peripheral arterial occlusive disease internally or surgically treated due to acute

ischemia

Table S1. Study criteria

Inclusion criteria

Patients who met all the following criteria were included in this study:

- 1. Patients aged \geq 20 years when consent was obtained
- 2. Patients with coronary artery lesions that were visually confirmed by coronary angiography and for which PCI was indicated by drug-eluting stent placement (as judged with reference to the package insert)
- 3. Patients administered antiplatelet drugs
- 4. Patients providing written consent after receiving an explanation of the contents of this clinical research (in case of an emergency, consent could be obtained from a designated representative)

Exclusion criteria

Patients who were participating or planning to participate in a clinical study that consisted of a clinical trial or intervention before the follow-up of this study was complete.

Patients who had acute coronary syndrome or coronary artery disease requiring elective intracoronary stenting and who had undergone PCI with DES implantation were eligible for the study. DES = drug-eluting stent, PCI = percutaneous coronary intervention.

Table S2. One-year cumulative incidence of primary and secondary endpoints

	Number of events	Incidence (%)
MACCE	261	4.4
All cause death	156	2.7
Non-fatal myocardial infarction	62	1.0
Non-fatal stroke	51	0.9
Stent thrombosis	17	0.3
Major bleeding (BARC type 3 and 5)	165	2.8
All bleedings	419	7.1

 $BARC = Bleeding \ Academic \ Research \ Consortium; \ MACCE = major \ adverse \ cardiac$ and cerebrovascular events.




Figure S1. Time to measurement of PRU 12–48 h after PCI

PCI = percutaneous coronary intervention; $PRU = P2Y_{12}$ reaction units.




Figure S2A. Time—to—event curves through 1 year for all—cause death according to platelet reactivity




Figure S2B. Time—to—event curves through 1 year for non—fatal MI according to platelet reactivity




Figure S2C. Time—to—event curves through 1 year for non—fatal stroke according to platelet reactivity




Figure S2D. Time—to—event curves through 1 year for stent thrombosis according to platelet reactivity




Figure S2E. Time—to—event curves through 1 year for all bleeding according to platelet reactivity

HPR = high P2Y₁₂ reaction units; LPR = low P2Y₁₂ reaction units; MI = myocardial infarction; OPR = optimal P2Y₁₂ reaction units; PRU = P2Y₁₂ reaction units.




Figure S3A. Time to event curves of ACS and non-ACS groups through 1 year (ACS patients)




Figure S3B. Time to event curves of ACS and non-ACS groups through 1 year (non-ACS patients)

ACS = acute coronary syndrome; CI = confidence interval; MACCE = major adverse cardiac and cerebrovascular events.




Figure S4A. One-year cumulative incidence of MACCE according to platelet reactivity by P2Y12 inhibitor at discharge




Figure S4B. One-year cumulative incidence of major bleeding according to platelet reactivity by P2Y₁₂ inhibitor at discharge

HPR = high $P2Y_{12}$ reaction units; HR = hazard ratio; LPR = low $P2Y_{12}$ reaction units; MACCE = major adverse cardiac and cerebrovascular events; OPR = optimal $P2Y_{12}$ reaction units; PRU = $P2Y_{12}$ reaction units.